tiprankstipranks
Trending News
More News >

Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential

Buy Rating for Vera Therapeutics Driven by Promising Phase III Results and Market Potential

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Vera Therapeutics (VERAResearch Report), retaining the price target of $70.00.

Don’t Miss TipRanks’ Half-Year Sale

Rami Katkhuda has given his Buy rating due to a combination of factors surrounding Vera Therapeutics’ promising clinical developments and market potential. The company is on track to release significant Phase III ORIGIN 3 study results, which are anticipated to show a clinically meaningful benefit in proteinuria reduction. This outcome could pave the way for an accelerated approval of atacicept in treating IgAN, a condition with a growing market and room for multiple successful treatments.
Furthermore, despite the current market pressures and competitive landscape, Katkhuda sees a disconnect between Vera’s current valuation and the potential of atacicept. The drug has shown promising results in stabilizing kidney function in earlier studies, and there is optimism that it will perform well against competitors like Otsuka’s sibeprenlimab. These factors, combined with expert feedback on the evolving treatment landscape, underpin the Buy rating for Vera Therapeutics.

According to TipRanks, Katkhuda is a 4-star analyst with an average return of 13.4% and a 38.73% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Tourmaline Bio, and VYNE Therapeutics.

In another report released on May 16, J.P. Morgan also maintained a Buy rating on the stock with a $68.00 price target.

Disclaimer & DisclosureReport an Issue

1